Novartis bets $9.7bn on RNA interference
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Speedy nod sets Alnylam up for its second launch
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
Hologic burns its aesthetics unit
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
Who will buy Qiagen?
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
Relugolix gets a Hero’s welcome in prostate cancer
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
AHA 2019 – The Medicines Company reaches for the stars
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Novo goes small with big Dicerna deal
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Puretech’s cautionary tale about pivotal study read-across
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
Amarin enters the home stretch
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.